基于抗组织纤维化的慢性肾脏病治疗新进展  

Progress in anti-fibrosis treatment of chronic kidney disease

作　　者：张东亮[1] 

机构地区：[1]北京大学国际医院肾内科,北京102206

出　　处：《首都医科大学学报》2015年第3期333-337,共5页Journal of Capital Medical University

基　　金：北京市自然科学基金(7132091)~~

摘　　要：慢性肾脏病是威胁健康的重大疾病,近年来针对其发生发展的核心环节——肾组织纤维化进行了许多研究。在肾组织纤维化发病机制方面,组成肾组织的不同细胞在纤维化进程中具有不同的作用,各自的可修复能力也大不相同,炎性细胞不同亚群也表现出促进或逆转纤维化的活性。针对这些结果,一些新的治疗措施正在进行临床前或临床研究,包括抗转化生长因子-β(trasfoming growth factor-β,TGF-β)、抗氧化应激、抗血管钙化、抗化学趋化因子治疗和干细胞治疗等。未来抑制、阻断、甚至逆转肾脏纤维化的治疗技术将成为可能。Chronic kidney disease（CKD） is one of the most serious diseases of human being.A lot of researches on the kidney fibrosis,which plays the core role in the progression of CKD,have been conducted recently.Many studies’ results indicated that different cells of kidney have different effects on tissue fibrosis and regeneration.Different subgroup of inflammatory cells may actively support the regeneration process.According to these researches,many new methods were developed to treat the kidney fibrosis,including antitransforming growth factor-β（TGF-β） treatment,anti-oxidative stress,anti-vascular calcification,and anti-chemokines treatments.Mesenchymal stem cells or other cells have been tested for treatment of kidney fibrosis.It will be possible to inhibit,stop,or even reverse kidney fibrosis in the future.

关 键 词：慢性肾脏病 纤维化 治疗 

分 类 号：R692[医药卫生—泌尿科学]